Trevor Clancy

Deep learning of antibody epitopes using molecular permutation vectors biorxiv.org/cgi/content/sh… #bioRxiv

The heterogeneity and rarity of sarcomas makes it challenging to develop successful therapies for sarcoma patients. This research addresses the need to develop further insights into potential biomarkers that may determine which patients are most likely... businesswire.com/news/home/2023…

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy bakersfield.com/ap/news/nec-on… via @Bakersfieldcali

CEPI støtter norske NEC @OncoImmunity som bruker kunstig intelligens i utviklingen av en bredspektret betakoronavaksine @DagensMedisin 🇳🇴 tinyurl.com/2p9ddh6t

A major milestone for our team! Congrats to all involved nec.com/en/press/20220…

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets: Press Releases | NEC nec.com/en/press/20220…

We are hiring! Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases. finn.no/job/employer/c…

@OncoImmunity is hiring! Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases. finn.no/job/employer/c…

Exciting to see our AI approach to develop universal blueprints for vaccine design now published in the peer review journal Scientific Reports nature.com/articles/s4159…

An artificial intelligence T-cell diagnostic test for COVID-19 businesswire.com/news/home/2020…

NEC’s AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine: Business Insights | NEC nec.com/en/global/insi…

Our "NK cell proliferomics" paper is out in @CellReports Congrats @AlinePfefferle "Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity" cell.com/cell-reports/f…

Vår porteføljebedrift Ultimovacs har hentet inn 370 millioner kroner i en overtegnet emisjon, og vil bli notert på Oslo Børs mandag 3. juni 2019 ntbinfo.no/pressemelding/… @OsloCancer @radforsk @Oslounivsykehus @UniOslo

scRNA-seq reveals heterogeneity in the CD56bright NK cell subset and nondramatic transitioning into CD56dim NK cells @Trevor_Clancy @AlinePfefferle and Herman Netskar biorxiv.org/content/10.110…

OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today lnkd.in/eVkqvmz